Viatris Pipeline Advances on Multiple Fronts: FDA Approves Generic Octreotide, OKs Weekly Contraceptive Patch for Review

Viatris Inc. (VTRS) delivered significant regulatory progress Thursday, with the FDA greenlighting its generic version of a key acromegaly treatment and clearing the pathway for a novel weekly contraceptive patch to reach the market.

Generic Octreotide Joins 2025 Injectable Lineup

The healthcare company achieved its fourth FDA approval for injectable medications this year with octreotide acetate for injectable suspension, positioning itself as a competitive player in the rare disease treatment space. The drug, a long-acting generic equivalent of Sandostatin LAR Depot, addresses symptoms associated with acromegaly and other rare conditions. This approval comes alongside three other injectable clearances: iron sucrose, paclitaxel, and liposomal amphotericin B, signaling strong momentum in Viatris’ injectable portfolio.

Weekly Contraceptive Patch on FDA’s Review Docket

More notably, the FDA has accepted Viatris’ New Drug Application for a weekly contraceptive patch formulation, setting July 30, 2026 as the target review completion date. The product combines 150 mcg norelgestromin with 17.5 mcg ethinyl estradiol in a transdermal delivery system designed for women with BMI below 30 kg/m² seeking non-invasive reversible contraception options. The weekly dosing format represents an alternative to daily pill regimens and other conventional methods, potentially expanding choices for women who prefer extended-interval dosing.

Gene Therapy and Sleep Disorder Programs Gain Traction

Beyond these headline developments, Viatris secured investigational new drug clearance for MR-146, an AAV-based gene therapy targeting neurotrophic keratopathy (NK), a sight-threatening corneal degenerative disease affecting approximately 73,000 Americans. The company plans to initiate Phase 1/2 trials in the first half of 2026.

Internationally, Japan’s PMDA accepted Viatris’ application for pitolisant in obstructive sleep apnea syndrome, with the company on track to file for narcolepsy indication by year-end. The Japanese trials demonstrated statistically significant improvements in daytime sleepiness (p=0.007) among CPAP-resistant patients on pitolisant, measured by the Epworth Sleepiness Scale—a meaningful result for a large underserved patient population.

In premarket trading on Nasdaq, VTRS shares reflected modest weakness, declining 0.34% to $11.66, though the pipeline breadth suggests multiple near-term catalysts across contraception, gene therapy, and neurological indications.